Discover trends, market shifts, and competitive outlooks for the dermatomycoses industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What Are the Projected Market Size and Growth Rates for the Dermatomycoses Market From 2025 To 2029?
In the past few years, the dermatomycoses market has expanded significantly. The market, which was valued at $14.12 billion in 2024, is projected to reach $14.95 billion in 2025, equating to a compound annual growth rate (CAGR) of 5.9%. This considerable growth during the historical period results from factors such as advancing antifungal treatments, growing incidences of fungal infections, heightened skin health consciousness, improved diagnostic strategies, and the growth of over-the-counter antifungal products.
Strong expansion is projected for the dermatomycoses market in the coming years, with estimations reaching $18.59 billion by 2029, achieving a compound annual growth rate (CAGR) of 5.6%. Factors contributing to this growth throughout the forecast period include increased aging demographics, the emergence of drug-resistant fungal strains, heightened demand for organic antifungal products, progressing biotechnological developments and research in antifungal studies, and growth in healthcare reach in emerging regions. The forecast period is also likely to see trendsetting changes such as the invention of new antifungal medications, enhancements in quick diagnostic methods, the incorporation of artificial intelligence in dermatology, advancements in nanotechnology-infused antifungal remedies, and pioneering work in microbiome-centered treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21934&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Dermatomycoses Market?
The dermatomycoses market is likely to grow due to the escalating prevalence of fungal infections. These infections are triggered by fungi that impact the skin, nails, hair, or even the internal organs, leading to assorted health complications. The unfettered use of broad-spectrum antibiotics causes an imbalance in the natural microbiome, offering an ideal environment for fungi to flourish and cause infections. Such an imbalance weakens the body’s natural defense systems, exposing people to opportunistic fungal infections. Dermatomycoses, caused by impure yeasts, dermatophytes, and molds, result in fungal diseases affecting different tissues and leading to common superficial and systemic infections. For example, in November 2023, the UK Health Security Agency, a public health regulator dedicated to safeguarding public health from infectious diseases, estimated a yearly incident rate of 6.5 million invasive fungal infections globally, which led to about 3.8 million deaths. Out of these, 2.5 million deaths were directly linked to these infections. Thus, the rise in fungal infections is fuelling the growth of the dermatomycoses market. Additionally, the soaring demand for oral drugs is anticipated to encourage the growth of the dermatomycoses market. Oral medications, including tablets, capsules, or fluids taken by mouth, and absorbed through the gastrointestinal tract, are increasingly in demand. The preference for oral medicines stems from their simple usage and effectiveness in managing diverse conditions, and they are often chosen over injections or other means of delivery. Oral drugs, with the help of systemic antifungal agents, can penetrate the affected skin, hair, or nails through bloodstream, ensuring a deeper and more extended treatment compared to topical applications. For example, the Centers for Disease Control and Prevention, a US-based governmental agency, reported in October 2022, that the dispensation of oral antivirals had risen by 57%, leaping from 643 per 100,000 individuals between April 24 and May 21, 2022, to 1,012 per 100,000 individuals between July 31 and August 28, 2022. Thus the burgeoning demand for oral drugs is fostering the expansion of the dermatomycoses market.
Which Key Market Segments Comprise the Dermatomycoses Market and Drive Its Revenue Growth?
The dermatomycoses market covered in this report is segmented –
1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
3) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegmentss:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus
3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide
4) By Immunomodulator: Interferon-Gamma, Thalidomide
5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals
6) By Other Drugs: Antihistamines, Antibacterial Agents
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21934&type=smp
Which Areas Are Leading Regions in the Dermatomycoses Market Expansion Across the Globe?
North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theDermatomycoses Market Direction?
Leading firms in the dermatomycoses market are prioritizing the development of investigational new drugs to enhance onychomycosis treatment and boost its effectiveness. Investigational new drugs (IND) are therapeutic compounds currently in the preclinical or clinical trial stages, being assessed for safety, efficacy, and regulatory approval potential before they become sanctioned treatments. For example, Vanda Pharmaceuticals Inc., a biopharmaceutical company from the US, was granted approval for its Investigational New Drug VTR-297 by the US Food and Drug Administration (FDA) in January 2024, targeted for onychomycosis treatment. The uniqueness of VTR-297 lies in its topical antifungal properties linked to its histone deacetylase (HDAC) inhibitory attributes, which sets it apart from conventional antifungal medications. It functions by attacking the fundamental cause of fungal proliferation, indicating potent antifungal activity against dermatophytes and other types of fungi. This innovative action mode could offer quicker and more effective treatment outcomes, while also lowering the chances of infection reappearance, fulfilling a critical gap in onychomycosis therapy.
View the full report here:
https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report
How Is the Dermatomycoses Market Conceptually Defined?
Dermatomycoses are a group of fungal infections affecting the skin, hair, and nails, primarily caused by dermatophytes, yeasts, or molds. These infections often lead to itching, scaling, redness, and skin inflammation, impacting overall skin health. The main goal of treatment is to eliminate the fungal infection, alleviate symptoms, and prevent recurrence through the use of antifungal medications, maintaining proper hygiene, and following effective skin care practices.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21934
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model